

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 January 2020 (09.01.2020)



(10) International Publication Number
WO 2020/009954 A1

(51) International Patent Classification:

A61K 33/04 (2006.01) A61K 33/42 (2006.01)
A61K 33/22 (2006.01)

(21) International Application Number:

PCT/US2019/040052

(22) International Filing Date:

01 July 2019 (01.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/693,503	03 July 2018 (03.07.2018)	US
62/693,502	03 July 2018 (03.07.2018)	US

(71) Applicant: **FENNEC PHARMACEUTICALS, INC.**
[US/US]; 68 TW Alexander Drive, Research Triangle Park,
NC 27709 (US).

(72) Inventors: **LEE, Christopher, McKinnon**; 113 White
Hill Drive, Holly Springs, NC 27540 (US). **LOVELACE,
Thomas, Claiborne**; 2030 Lazio Lane, Apex, NC 27502
(US). **MOORE, Joseph, Alexander, III**; 1012 Lake Val-
ley Drive, Wake Forest, NC 27587 (US). **KIRSCHNER,
Daniel, Logan**; 6923 Dawnalia Court, Raleigh, NC 27617
(US).


(74) Agent: **BROWN, Bernard, A., III** et al.; Brinks Gilson &
Lione, P.O. Box 110285, Research Triangle Park, NC 27709
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: FORMULATIONS OF ANHYDROUS SODIUM THIOSULFATE

FIG. 6



(57) Abstract: Described herein is anhydrous sodium thiosulfate, meth-
ods for synthesizing anhydrous sodium thiosulfate, pharmaceutical com-
positions thereof, and methods of treating ototoxicity. Anhydrous sodium
thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridini-
um chloride. The anhydrous sodium thiosulfate is formulated into a phar-
maceutical composition comprising a buffer and solvent. These compo-
sitions are useful for eliminating or reducing ototoxicity in pediatric pa-
tients receiving platinum based chemotherapeutics.

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*